Pyxis Oncology【PYXS】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

2.26

買値

2.25

売値

2.26

出来高

5,457,154

3.80 日の範囲 4.31

1.35 52 週間の範囲 6.85

時価総額

134.393M

前日終値

4.16

始値

4.25

時刻

100

2.26

(formt)

最終取引時間

財務取引量

US$ 21,842,394

VWAP

4.0025

平均取引量 (3 か月)

557,504

発行済株式数

59,465,729

配当利回り

PER

-3.09

1 株当たり利益 (EPS)

-1.24

歳入

純利益

-73.79M

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the ... Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

pyxisoncology.com

本社

Wilmington, Delaware, USA

設立

Pyxis Oncology Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker PYXS. The last closing price for Pyxis Oncology was US$4.16. Over the last year, Pyxis Oncology shares have traded in a share price range of US$ 1.35 to US$ 6.85.

Pyxis Oncology currently has 59,465,729 shares in issue. The market capitalisation of Pyxis Oncology is US$247.38 million. Pyxis Oncology has a price to earnings ratio (PE ratio) of -3.09.

Form 8-K - Current report

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and...

Form S-8 - Securities to be offered to employees in employee benefit plans

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at...

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-2.49	-52.4210526316	4.75	5.5	1.92	757379	4.21886701	CS
4	-1.23	-35.2435530086	3.49	5.5	1.92	617304	4.13814843	CS
12	-1.4	-38.2513661202	3.66	5.5	1.92	557504	3.78801334	CS
26	-1.85	-45.0121654501	4.11	5.5	1.92	513247	3.62608967	CS
52	0.84	59.1549295775	1.42	6.85	1.35	556140	4.07363843	CS
156	-10.34	-82.0634920635	12.6	13.3	1.1	596779	3.98208724	CS
260	-16.74	-88.1052631579	19	19	1.1	585556	4.16255027	CS

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
FBRXForte Biosciences Inc	US$ 13.60 (129.53%)	28.92M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	279.33M
XCURExicure Inc	US$ 11.01 (89.18%)	22.91M
AGFYAgrify Corporation	US$ 37.4635 (68.00%)	921.45k
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	198.66M
SKKSKK Holdings Limited	US$ 4.55 (-47.28%)	816.93k
QMMMQMMM Holdings Limited	US$ 0.713999 (-43.78%)	4.61M
XTKGX3 Holdings Company Ltd	US$ 0.0901 (-37.82%)	5.95M
PRFXPainReform Ltd	US$ 1.02 (-27.14%)	5.09M
GLEGlobal Engine Group Holding Ltd	US$ 3.81 (-26.59%)	230.23k
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.191 (17.39%)	662.68M
DBGIDigital Brands Group Inc	US$ 0.1345 (15.35%)	326.45M
NVDANVIDIA Corporation	US$ 145.89 (-0.76%)	309.57M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	283.09M
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	200.06M